Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Two Patents, Seven Patent Applications Related to RNAi

USPTO Publishes Two Patents, Seven Patent Applications Related to RNAi
Title: Oligoribonucleotides and Ribonucleases for Cleaving RNA
Number: 7,432,250, 7,432,249
Filed: Oct. 25, 2002
Inventor: Stanley Crooke, Isis Pharmaceuticals
The patents, their abstracts state, claim “oligomeric compounds including oligoribonucleotides and oligoribonucleosides … that have subsequences of 2'-pentoribofuranosyl nucleosides that activate dsRNase. The oligoribonucleotides and oligoribonucleosides can include substituent groups for increasing binding affinity to complementary nucleic acid strand as well as substituent groups for increasing nuclease resistance. The oligomeric compounds are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics.”
The patents also claim “mammalian ribonucleases, i.e., enzymes that degrade RNA, and substrates for such ribonucleases,” according to the abstracts. “Such a ribonuclease is referred to herein as a dsRNase, wherein "ds" indicates the RNase's specificity for certain double-stranded RNA substrates. The artificial substrates for the dsRNases described herein are useful in preparing affinity matrices for purifying mammalian ribonuclease as well as non-degradative RNA-binding proteins.”

Title: Composition and Methods of RNAi Therapeutics for Treatment of Cancer and Other Neovascularization Diseases
Number: 20080241198
Filed: June 29, 2007
Lead Inventor: Yijia Liu, Intradigm
The patent application, its abstract states, claims “compositions and methods … for treatment of diseases involving unwanted neovascularization. The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological [neovascularization] tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference … [and] can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists” are covered by the patent application, the abstract adds. “The compositions and methods can be used for the treatment of [neovascularization] diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.”

Title: Vector Constructs
Number: 20080241894
Filed: March 26, 2008
Lead Inventor: Geert Plaetinck, Devgen
The patent application, its abstract states, claims “improved vector constructs useful in the expression of double-stranded RNA. … The constructs are particularly useful for expression of double-stranded RNA in vitro and in vivo.”

Title: Nucleotide-Cochleate Compositions and Methods of Use
Number: 20080242625
Filed: April 11, 2005 PCT Filed: April 11, 2005
Lead Inventor: Raphael Mannino, BioDelivery Sciences International
The invention “is directed to cochleate composition that [includes] a nucleotide,” the patent application’s abstract states. “The nucleotide may generally be bound via a linker to a component of the cochleate, or to a lipophilic tail. Additionally or alternatively, the nucleotide may be associated with a transfection agent. The … invention also includes methods for making and using the compositions provided herein.”

Title: Novel RNA Interference Methods Using DNA-RNA Duplex Constructs
Number: 20080242627
Filed: Oct. 11, 2007
Lead Inventor: Shao-Yao Ying, University of Southern California
The invention, according to the patent application’s abstract, “provides novel compositions and methods for suppressing the function or activity of a targeted gene through a novel intracellular piRNA-mediated RNAi mechanism, using RNA-DNA duplex constructs. The invention further provides novel methods and compositions for generating or producing RNA-DNA duplex agents, whose quantity is high enough to be used for the invention's gene silencing transfection and possibly in therapeutics applications. This improved RNA-polymerase chain reaction method utilizes thermocycling steps of promoter-linked DNA or RNA template synthesis, in vitro transcription and then reverse transcription to bring up the amount of RNA-DNA duplexes up to two thousand folds within one round of the above procedure for using in D-RNAi-directed gene silencing.”

Title: Inhibiting Gene Expression with dsRNA
Number: 20080242628
Filed: Oct. 31, 2007
Lead Inventor: Magdalena Zernicka-Goetz, Cancer Research Technology (Alnylam Pharmaceuticals)
The invention, the patent application’s abstract states, “relates to the specific inhibition of gene expression in mammals by bringing the target gene into contact with double-stranded RNA.”

Title: Multi-Targeting Short Interfering RNAs
Number: 20080242632
Filed: Jan. 29, 2008
Lead Inventor: John Rossi, City of Hope
The invention “relates to novel short interfering RNA molecules that are multi-targeted,” the patent application’s abstract states. “More specifically, the … invention relates to siRNA molecules that target two or more sequences. In one embodiment, multi-targeting siRNA molecules are designed to incorporate features of siRNA molecules and features of microRNA molecules. In another embodiment, multi-targeting siRNA molecules are designed so that each strand is directed to separate targets.” 

Title: Modified Polynucleotides for Reducing Off-Target Effects in RNA Interference
Number: 20080242851
Filed: Sept. 19, 2007
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
The patent application, its abstract states, claims “methods and compositions for performing RNA interference with decreased off-target effects. … The methods and compositions permit effective and efficient applications of RNA interference to applications such as diagnostics and therapeutics through the use of modifications to the siRNA. Uniquely modified siRNAs have been developed that reduce off-target effects incurred in gene-silencing. The modifications comprise 2'-O-alkyl or mismatch modification(s) at specific positions on the sense and/or antisense strands.”

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.